Yahoo
KSE - Delayed Quote KRW

JW Pharmaceutical Corporation (001067.KS)

49,100.00 -500.00 (-1.01%)
At close: November 2 at 3:30:22 PM GMT+9
View in AlphaSpace Currency in KRW All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
820,861,880.44
775,298,057.92
719,375,756.34
748,526,707.81
684,351,099.24
Cost of Revenue
432,641,462.62
415,984,174.25
395,877,577.21
412,984,311.74
396,396,561.50
Gross Profit
388,220,417.82
359,313,883.67
323,498,179.13
335,542,396.07
287,954,537.74
Operating Expense
273,819,353
264,852,896
240,765,665
234,625,757
225,175,477
Operating Income
114,401,064.82
94,460,987.67
82,732,514.13
100,916,639.07
62,779,060.74
Net Non Operating Interest Income Expense
298,754.26
-773,614.22
-4,915,169
-5,272,767.62
-2,737,994.41
Pretax Income
115,304,998.59
88,836,028.39
82,419,534.31
54,836,449.90
45,361,952.26
Tax Provision
14,023,926.91
27,324,835.58
17,379,413.44
16,406,190.34
15,509,392.09
Net Income Common Stockholders
101,281,071.68
61,511,192.81
65,040,120.87
37,006,333.99
31,891,678.69
Basic EPS
4.19k
2.53k
2.64k
1.47k
1.24k
Diluted EPS
4.19k
2.53k
2.64k
1.47k
1.24k
Basic Average Shares
24,162.88
24,274.35
24,599.14
25,106.06
25,674.63
Diluted Average Shares
24,162.88
24,274.35
24,599.14
25,106.06
25,674.63
Total Operating Income as Reported
114,401,065.20
94,460,987.93
82,488,136.81
100,303,770.11
62,960,870.72
Total Expenses
706,460,815.62
680,837,070.25
636,643,242.21
647,610,068.74
621,572,038.50
Net Income from Continuing & Discontinued Operation
101,281,071.68
61,511,192.81
65,040,120.87
37,006,333.99
31,891,678.69
Normalized Income
107,397,096.66
66,332,293
65,386,604.70
39,312,991.95
39,096,071.44
Interest Income
--
3,238,320
4,867,678
5,893,147
5,321,509
Interest Expense
--
4,423,731
10,032,865
12,561,689
9,386,791
Net Interest Income
298,754.26
-773,614.22
-4,915,169
-5,272,767.62
-2,737,994.41
EBIT
113,199,836.54
93,259,759.39
92,452,399.31
67,398,138.90
54,748,743.26
EBITDA
132,691,422.54
112,007,357.39
111,553,628.31
89,972,736.90
71,585,063.26
Reconciled Cost of Revenue
432,641,462.62
415,984,174.25
395,877,577.21
412,984,311.74
396,396,561.50
Reconciled Depreciation
19,491,586
18,747,598
19,101,229
22,574,598
16,836,320
Net Income from Continuing Operation Net Minority Interest
101,281,071.68
61,511,192.81
65,040,120.87
37,006,333.99
31,891,678.69
Total Unusual Items Excluding Goodwill
-6,962,883
-6,962,883
-439,068
-3,291,389
-10,947,313
Total Unusual Items
-6,962,883
-6,962,883
-439,068
-3,291,389
-10,947,313
Normalized EBITDA
139,654,305.54
118,970,240.39
111,992,696.31
93,264,125.90
82,532,376.26
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-846,858.02
-2,141,782.81
-92,584.17
-984,731.04
-3,742,920.25
12/31/2022 - 9/29/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: